Replimune Group Inc (REPL)

Jan 21, 2025

Barclays maintains Replimune stock with $17 target By Investing.com - Investing.com UK

Jan 21, 2025

Jan 21, 2025

Replimune stock soars on FDA priority review for melanoma treatment - MSN

Jan 21, 2025

Jan 21, 2025

Replimune stock price target raised to $27 by BMO Capital - Investing.com South Africa

Jan 21, 2025

Jan 21, 2025

Replimune Stock Soars 16% on FDA Priority Review for Advanced Me - GuruFocus.com

Jan 21, 2025

Jan 21, 2025

Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy - Yahoo Finance

Jan 21, 2025

Jan 21, 2025

Replimune stock soars on FDA priority review for melanoma treatment By Investing.com - Investing.com Australia

Jan 21, 2025

Jan 21, 2025

Replimune Group (NASDAQ:REPL) Shares Gap UpTime to Buy? - MarketBeat

Jan 21, 2025

Jan 21, 2025

Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday - Benzinga

Jan 21, 2025

Jan 21, 2025

FDA accepts Replimune's advanced melanoma therapy BLA - Investing.com

Jan 21, 2025

Jan 21, 2025

Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma - The Manila Times

Jan 21, 2025

Jan 21, 2025

FDA Grants Priority Review to Replimune's Melanoma Treatment RP1, Breakthrough Therapy Status Secured - StockTitan

Jan 21, 2025

Jan 21, 2025

JPMorgan Chase & Co. Raises Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jan 21, 2025

Jan 17, 2025

Trend Tracker for (REPL) - Stock Traders Daily

Jan 17, 2025

Jan 16, 2025

Replimune's SWOT analysis: biotech firm's stock poised for growth in oncology - MSN

Jan 16, 2025

Jan 14, 2025

Replimune Group (NASDAQ:REPL) Trading Down 6.6%Here's Why - MarketBeat

Jan 14, 2025

Jan 12, 2025

Barclays PLC Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jan 12, 2025

Jan 12, 2025

Barclays PLC Has $1.74 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Jan 12, 2025

Jan 11, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 11, 2025

Jan 10, 2025

Replimune Awards Equity Incentives to 30 New Hires, Including 253,820 Shares in Options and RSUs - StockTitan

Jan 10, 2025

Jan 10, 2025

Replimune Group Inc (REPL-Q) QuotePress Release - The Globe and Mail

Jan 10, 2025

Jan 08, 2025

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials - The Manila Times

Jan 08, 2025

Jan 08, 2025

Replimune Launches Two Major Clinical Trials for Melanoma and Liver Cancer Treatment RP2 - StockTitan

Jan 08, 2025

Jan 04, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives $17.29 Consensus PT from Brokerages - Defense World

Jan 04, 2025

Jan 02, 2025

Replimune Group (NASDAQ:REPL) Stock Price Up 9.5%What's Next? - MarketBeat

Jan 02, 2025

Jan 01, 2025

Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Jan 01, 2025

Dec 30, 2024

Geode Capital Management LLC Increases Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Dec 30, 2024

Dec 30, 2024

Geode Capital Management LLC Acquires 217,308 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Dec 30, 2024

Dec 29, 2024

Replimune's stock surges 19% after-hours on FDA BLA submission - MSN

Dec 29, 2024

Dec 28, 2024

Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Barclays PLC - Defense World

Dec 28, 2024

Dec 23, 2024

Replimune Group to Present at J.P. Morgan Healthcare Conference: Key Biotech Updates Coming - StockTitan

Dec 23, 2024

Dec 23, 2024

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Dec 23, 2024

Dec 23, 2024

State Street Corp Buys 1,182,181 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Dec 23, 2024

Dec 22, 2024

Jane Street Group LLC Sells 274,078 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Dec 22, 2024

Dec 20, 2024

Replimune Group (NASDAQ:REPL) Trading 8.2% HigherTime to Buy? - MarketBeat

Dec 20, 2024

Dec 20, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,759 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Dec 20, 2024

Dec 18, 2024

Insider Selling: Replimune Group, Inc. (NASDAQ:REPL) CEO Sells 10,000 Shares of Stock - MarketBeat

Dec 18, 2024

Dec 18, 2024

Replimune CEO Sushil Patel sells $124,200 in company stock - Investing.com

Dec 18, 2024

Dec 18, 2024

Replimune CEO Sushil Patel sells $124,200 in company stock By Investing.com - Investing.com Australia

Dec 18, 2024

Dec 18, 2024

Wellington Management Group LLP Decreases Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Dec 18, 2024

Dec 18, 2024

BNP Paribas Financial Markets Buys 6,748 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Dec 18, 2024

Dec 17, 2024

Replimune Group (NASDAQ:REPL) Trading Down 4.7%Here's Why - MarketBeat

Dec 17, 2024

Dec 17, 2024

Replimune management to meet with Jefferies - Nasdaq

Dec 17, 2024

Dec 16, 2024

When (REPL) Moves Investors should Listen - Stock Traders Daily

Dec 16, 2024

Dec 15, 2024

Replimune's SWOT analysis: biotech's melanoma treatment stock nears key milestones By Investing.com - Investing.com South Africa

Dec 15, 2024

Dec 15, 2024

Replimune's SWOT analysis: biotech's melanoma treatment stock nears key milestones - Investing.com India

Dec 15, 2024